Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Enanta Pharmaceutica (ENTA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,885,680
  • Shares Outstanding, K 19,442
  • Annual Sales, $ 206,630 K
  • Annual Income, $ 71,960 K
  • 36-Month Beta 1.27
  • Price/Sales 9.13
  • Price/Cash Flow 25.53
  • Price/Book 4.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.07
  • Number of Estimates 4
  • High Estimate 0.20
  • Low Estimate -0.30
  • Prior Year 0.61
  • Growth Rate Est. (year over year) -111.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
73.05 +41.20%
on 01/17/19
103.68 -0.51%
on 02/15/19
+27.36 (+36.10%)
since 01/15/19
3-Month
64.08 +60.96%
on 12/24/18
103.68 -0.51%
on 02/15/19
+23.79 (+29.98%)
since 11/15/18
52-Week
64.08 +60.96%
on 12/24/18
127.77 -19.27%
on 07/06/18
+21.81 (+26.81%)
since 02/15/18

Most Recent Stories

More News
Factors of Influence in 2019, Key Indicators and Opportunity within BCE, Nektar Therapeutics, Hormel Foods, Enanta Pharmaceuticals, MongoDB, and Regal Beloit -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of BCE, Inc. (NYSE:BCE), Nektar...

RBC : 83.96 (+1.57%)
HRL : 43.20 (+0.35%)
BCE : 43.32 (+0.70%)
ENTA : 103.15 (+6.34%)
MDB : 100.30 (+1.02%)
NKTR : 41.69 (-2.18%)
Noteworthy Wednesday Option Activity: ENTA, INSM, PPC

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Enanta Pharmaceuticals Inc , where a total volume of 1,646 contracts has been traded...

ENTA : 103.15 (+6.34%)
Enanta Pharmaceu Shares Up 20.9% Since SmarTrend's Buy Recommendation (ENTA)

SmarTrend identified an Uptrend for Enanta Pharmaceu (NASDAQ:ENTA) on January 7th, 2019 at $74.33. In approximately 1 month, Enanta Pharmaceu has returned 20.93% as of today's recent price of $89.89.

ENTA : 103.15 (+6.34%)
Enanta Pharmaceuticals (ENTA) Lags Q1 Earnings and Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -14.38% and -4.34%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?...

ENTA : 103.15 (+6.34%)
Enanta Pharmaceuticals: Fiscal 1Q Earnings Snapshot

WATERTOWN, Mass. (AP) _ Enanta Pharmaceuticals Inc. (ENTA) on Wednesday reported fiscal first-quarter net income of $26 million.

ENTA : 103.15 (+6.34%)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31, 2018

--Royalty revenue for the quarter increased to $69.9 million

ENTA : 103.15 (+6.34%)
Enanta Pharmaceuticals (ENTA) Earnings Expected to Grow: Should You Buy?

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ENTA : 103.15 (+6.34%)
Enanta Pharmaceuticals to Host Conference Call on February 6th at 4:30 pm ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2018

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today...

ENTA : 103.15 (+6.34%)
Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Business Outlook for 2019 during the 37th Annual J.P. Morgan Healthcare Conference

--Phase 1 clinical study of HBV core inhibitor EDP-514 planned to begin second half of 2019

JPM : 105.55 (+3.06%)
ENTA : 103.15 (+6.34%)
Enanta Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference

SOURCE: Enanta Pharmaceuticals, Inc.">

ENTA : 103.15 (+6.34%)
JPM : 105.55 (+3.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is in the Top 1%. Long term indicators mostly agree with the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade ENTA with:

Business Summary

Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown,...

See More

Key Turning Points

2nd Resistance Point 108.30
1st Resistance Point 105.73
Last Price 103.15
1st Support Level 98.52
2nd Support Level 93.89

See More

52-Week High 127.77
Fibonacci 61.8% 103.44
Last Price 103.15
Fibonacci 50% 95.93
Fibonacci 38.2% 88.41
52-Week Low 64.08

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar